Abstract
BACKGROUND: Autophagy is balanced machinery that supports anti-malignant mechanism via the removal of dysfunctional proteins, ROS and DNA abnormalities. Appropriate autophagic machinery is fundamental for mutant eradication and suitable genomic constancy thus it prevents the genetic faults aggregation which contributes to malignant conversion. This article focuses on the application of liposomal-formulated Nano-medicine as prospective therapy for colon carcinoma and the complemented autophagic deviation. RESEARCH DESIGN AND METHODS: Colon carcinoma was induced experimentally in rat model via 3-Methyl cholantherene (3-MCA) for 6 months proceeded with liposomal Isethione, Turmeric and Adriamycin treatment for 1 month and was further compared with their non-liposomal analogue. Concomitant supplementation with the aforementioned liposomal-formulated Nano-medicine influence on the gene expression of autophagy biomarkers including X-box binding protein 1 (XBP), C/EBP homologous protein (CHOP), activating transcription factor 4 (ATF-4) and Beclin in addition to, angiogenic biomarker (NOX) and oxidative stress biomarker (Butryl cholinesterase) was investigated. RESULTS: Liposomal-formulated Nano-medicine modulated the deviated autophagy biomarkers and oxidative and nitosative stress biomarkers in addition to, modulating histomorphological changes induced post 3-MCA colorectal cancer induction. Autophagy was involved in all steps of colon cancer progression and apoptosis. CONCLUSION: liposomal-formulated Nano-medicine might be a prospective candidate for colorectal carcinoma treatment via modulating autophagy XBP/ATF4/Beclin/CHOP.